In the BioHarmony Drug Report Database
Belantamab
Blenrep (belantamab) is an antibody pharmaceutical. Belantamab was first approved as Blenrep on 2020-08-25. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target tumor necrosis factor receptor superfamily member 17.
Trade Name
|
Blenrep |
|---|---|
Common Name
|
belantamab |
ChEMBL ID
|
CHEMBL4298208 |
Indication
|
multiple myeloma |
Drug Class
|
Monoclonal antibodies: tumors |
Image (chem structure or protein)
